DE602006014814D1 - Materialien und verfahren zur änderung einer immunreaktion auf exogene und endogene immunogene, einschliesslich genidentischer und nicht-genidentischer zellen, gewebe oder organe - Google Patents

Materialien und verfahren zur änderung einer immunreaktion auf exogene und endogene immunogene, einschliesslich genidentischer und nicht-genidentischer zellen, gewebe oder organe

Info

Publication number
DE602006014814D1
DE602006014814D1 DE602006014814T DE602006014814T DE602006014814D1 DE 602006014814 D1 DE602006014814 D1 DE 602006014814D1 DE 602006014814 T DE602006014814 T DE 602006014814T DE 602006014814 T DE602006014814 T DE 602006014814T DE 602006014814 D1 DE602006014814 D1 DE 602006014814D1
Authority
DE
Germany
Prior art keywords
exogenous
genidential
cells
endogenous
organs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014814T
Other languages
English (en)
Inventor
Elazer R Edelman
Helen Marie Nugent
Heiko Methe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Pervasis Therapeutics Inc
Original Assignee
Massachusetts Institute of Technology
Pervasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Pervasis Therapeutics Inc filed Critical Massachusetts Institute of Technology
Publication of DE602006014814D1 publication Critical patent/DE602006014814D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
DE602006014814T 2005-04-21 2006-04-21 Materialien und verfahren zur änderung einer immunreaktion auf exogene und endogene immunogene, einschliesslich genidentischer und nicht-genidentischer zellen, gewebe oder organe Active DE602006014814D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67341705P 2005-04-21 2005-04-21
US68221705P 2005-05-18 2005-05-18
PCT/US2006/015555 WO2006116357A1 (en) 2005-04-21 2006-04-21 Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs

Publications (1)

Publication Number Publication Date
DE602006014814D1 true DE602006014814D1 (de) 2010-07-22

Family

ID=36695000

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014814T Active DE602006014814D1 (de) 2005-04-21 2006-04-21 Materialien und verfahren zur änderung einer immunreaktion auf exogene und endogene immunogene, einschliesslich genidentischer und nicht-genidentischer zellen, gewebe oder organe

Country Status (11)

Country Link
US (3) US20090087414A1 (de)
EP (1) EP1874919B1 (de)
JP (2) JP5174656B2 (de)
CN (1) CN101268183B (de)
AT (1) ATE470701T1 (de)
AU (1) AU2006238892B2 (de)
CA (1) CA2605080A1 (de)
DE (1) DE602006014814D1 (de)
ES (1) ES2347078T3 (de)
HK (1) HK1116829A1 (de)
WO (1) WO2006116357A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5174656B2 (ja) 2005-04-21 2013-04-03 マサチューセッツ インスティテュート オブ テクノロジー 同系または非同系の細胞、組織または器官を含む、外因性免疫原および内因性免疫原に対する免疫応答を改変するための材料および方法
CA2818182C (en) 2005-06-21 2015-04-14 Shire Regenerative Medicine, Inc. Methods and compositions for enhancing vascular access
US20100092532A1 (en) * 2006-11-07 2010-04-15 Helen Marie Nugent Materials and Methods for Treating and Managing Angiogenesis-Mediated Diseases
US9192471B2 (en) 2007-01-08 2015-11-24 Millipede, Inc. Device for translumenal reshaping of a mitral valve annulus
WO2008121331A1 (en) * 2007-03-30 2008-10-09 Pervasis Therapeutics, Inc. Materials and methods for treating nerve damage and promoting nerve repair and regeneration
WO2009020650A2 (en) * 2007-08-08 2009-02-12 Pervasis Therapeutics, Inc. Materials and methods for treating and managing wounds and the effects of trauma
EP2535063A1 (de) * 2007-08-08 2012-12-19 Pervasis Therapeutics, Inc. Materialien und Verfahren zur Behandlung von Schäden des Skelettsystems und zur Förderung der Reparatur und Regeneration des Skelettsystems
AU2009326818A1 (en) 2008-12-11 2011-07-07 The Govenors Of The University Of Alberta Methods and systems for inducing immunologic tolerance to non-self antigens
US20120053680A1 (en) 2010-08-24 2012-03-01 Bolling Steven F Reconfiguring Heart Features
CN104244999B (zh) * 2012-03-12 2017-02-22 富士胶片株式会社 组织修复材料的制造方法
US10849755B2 (en) 2012-09-14 2020-12-01 Boston Scientific Scimed, Inc. Mitral valve inversion prostheses
US10543088B2 (en) 2012-09-14 2020-01-28 Boston Scientific Scimed, Inc. Mitral valve inversion prostheses
US9180005B1 (en) 2014-07-17 2015-11-10 Millipede, Inc. Adjustable endolumenal mitral valve ring
US20160121023A1 (en) * 2014-10-30 2016-05-05 Massachusetts Institute Of Technology Materials and Methods for Rescue of Ischemic Tissue and Regeneration of Tissue Integrity During Resection, Engraftment and Transplantation
CN111110401B (zh) 2015-02-13 2022-03-29 波士顿科学国际有限公司 使用旋转锚固件的瓣膜置换
CA2996944A1 (en) * 2015-08-28 2017-03-09 Ctm@Crc Ltd. Products and methods for activating and/or expanding t cells
US10335275B2 (en) 2015-09-29 2019-07-02 Millipede, Inc. Methods for delivery of heart valve devices using intravascular ultrasound imaging
CN111329541B (zh) 2015-11-17 2023-09-19 波士顿科学国际有限公司 用于使心脏瓣环重新定形的可植入装置和输送系统
CN110381887B (zh) 2017-02-10 2022-03-29 波士顿科学国际有限公司 用于重塑心脏瓣膜环的可植入装置和输送系统
JP6906760B2 (ja) * 2017-03-28 2021-07-21 国立大学法人京都工芸繊維大学 持効性／徐放性骨破壊阻止剤
JP2022513113A (ja) * 2018-11-26 2022-02-07 マサチューセッツ インスティテュート オブ テクノロジー 免疫寛容のための組成物および方法
CN112546665B (zh) * 2020-12-01 2022-03-01 晨光生物科技集团股份有限公司 一种去除花椒中塑化剂的方法及花椒油树脂的制备方法和花椒油树脂

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US614039A (en) * 1898-11-08 turney
US4418691A (en) * 1981-10-26 1983-12-06 Massachusetts Institute Of Technology Method of promoting the regeneration of tissue at a wound
US4787900A (en) * 1982-04-19 1988-11-29 Massachusetts Institute Of Technology Process for forming multilayer bioreplaceable blood vessel prosthesis
US4820626A (en) * 1985-06-06 1989-04-11 Thomas Jefferson University Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surface itself
IL78950A (en) 1985-06-06 1991-12-15 Univ Jefferson Coating for prosthetic devices
US4732155A (en) * 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US5863531A (en) 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
CA1340581C (en) * 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5804178A (en) * 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5567612A (en) * 1986-11-20 1996-10-22 Massachusetts Institute Of Technology Genitourinary cell-matrix structure for implantation into a human and a method of making
US5736372A (en) * 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US6309635B1 (en) * 1986-11-20 2001-10-30 Children's Medical Center Corp. Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo
US5202120A (en) * 1987-09-11 1993-04-13 Case Western Reserve University Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
US4945086A (en) 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
CH676195A5 (de) * 1988-10-07 1990-12-28 Sulzer Ag
US5527532A (en) * 1989-11-13 1996-06-18 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
AU6747790A (en) * 1989-11-13 1991-06-13 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5540928A (en) * 1991-02-27 1996-07-30 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
ATE237682T1 (de) 1991-07-15 2003-05-15 Oklahoma Med Res Found Universale spenderzellen
US5336615A (en) 1992-01-06 1994-08-09 Yale University Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity
US5399665A (en) * 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) * 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
GB9306449D0 (en) 1993-03-29 1993-05-19 Nat Heart Research Fund Tissue equivalents
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US6176874B1 (en) * 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
AU2399495A (en) 1994-04-29 1995-11-29 W.L. Gore & Associates, Inc. Improved blood contact surfaces using endothelium on a subendothelial extracellular matrix
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US6911216B1 (en) * 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
WO1996011671A1 (en) * 1994-10-12 1996-04-25 Focal, Inc. Targeted delivery via biodegradable polymers
US5914268A (en) * 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5716404A (en) * 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5766584A (en) * 1995-06-02 1998-06-16 Massachusetts Institute Of Technology Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells
US6615071B1 (en) * 1995-09-20 2003-09-02 Board Of Regents, The University Of Texas System Method and apparatus for detecting vulnerable atherosclerotic plaque
US6886568B2 (en) * 1998-04-08 2005-05-03 The Johns Hopkins University Method for fabricating cell-containing implants
EP1144594A1 (de) * 1998-11-24 2001-10-17 Regents Of The University Of Minnesota Transgenische zirkulierende endothelzellen
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
US6387116B1 (en) * 1999-06-30 2002-05-14 Pharmasonics, Inc. Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
AU2001243248A1 (en) 2000-02-23 2001-09-03 Smith Kline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
JP4871476B2 (ja) * 2000-03-13 2012-02-08 バイオコンパティブルズ ユーケー リミテッド 塞栓組成物
EP1263484B1 (de) * 2000-03-15 2007-05-16 OrbusNeich Medical, Inc. Beschichtung welche ein anhaften von endothelzellen stimuliert
US6506398B1 (en) * 2000-04-28 2003-01-14 Hosheng Tu Device for treating diabetes and methods thereof
AU2001277112A1 (en) 2000-07-21 2002-02-05 Board Of Regents, The University Of Texas System Device providing regulated growth factor delivery for the regeneration of peripheral nerves
US6696483B2 (en) * 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6565601B2 (en) * 2000-11-15 2003-05-20 Micro Therapeutics, Inc. Methods for vascular reconstruction of diseased arteries
US6638709B2 (en) 2000-12-27 2003-10-28 Ortec International, Inc. Processes for making cryopreserved composite living constructs and products resulting therefrom
AP2003002828A0 (en) 2001-01-16 2003-09-30 Vascular Therapies Llc Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts.
US6723131B2 (en) * 2001-02-28 2004-04-20 The Cleveland Clinic Foundation Composite bone marrow graft material with method and kit
WO2003026489A2 (en) 2001-09-28 2003-04-03 University Of Florida Biopolymer and biopolymer-cell compositions for nerve tissue repair
AU2002363322A1 (en) * 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
AU2002360674A1 (en) * 2001-12-21 2003-07-30 The United States Of America Represented By The Secretary Of The U.S. Department Of The Navy In increasing gene transfer efficiency by pre-incubation with endothelial cells
US7297540B2 (en) 2002-01-15 2007-11-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
US20040047843A1 (en) * 2002-02-12 2004-03-11 Uab Research Foundation Method for spinal cord reconnection
WO2003083044A2 (en) 2002-03-25 2003-10-09 Condros, Inc. Tissue analogs for in vitro testing and method of use therefor
US20050008629A1 (en) * 2002-05-08 2005-01-13 Interpore Orthopaedics, A Delaware Corporation Encapsulated AGF cells
AU2003250858A1 (en) 2002-06-28 2004-01-19 Novartis Ag Use of organic compounds
GB0322789D0 (en) 2003-09-30 2003-10-29 Lifeforce Group Plc Blood pack for leukocyte banking
WO2005052138A1 (en) * 2003-11-19 2005-06-09 Wisconsin Alumni Research Foundation Cryopreservation of pluripotent stem cells
WO2005072417A2 (en) 2004-01-27 2005-08-11 The Ohio State University Research Foundation Vascular endothelial growth factors and methods of their use
CN101080486B (zh) 2004-04-23 2012-05-16 佰欧益股份有限公司 多谱系祖细胞
FR2869533B1 (fr) 2004-05-03 2006-07-28 Sedat Sa Seringue pour interventions medicales et necessaire de reconstitution de substances extemporanees comportant une telle seringue
US7842304B2 (en) 2004-10-29 2010-11-30 Nexeon Medsystems, Inc. Methods and apparatus for treating an injured nerve pathway
WO2006062909A2 (en) 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
WO2006062871A2 (en) 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Materials and methods for minimally-invasive administration of a cell-containing flowable composition
CA2881343A1 (en) 2004-12-08 2006-06-15 Shire Regenerative Medicine, Inc. Methods and compositions for enhancing vascular access
JP5174656B2 (ja) 2005-04-21 2013-04-03 マサチューセッツ インスティテュート オブ テクノロジー 同系または非同系の細胞、組織または器官を含む、外因性免疫原および内因性免疫原に対する免疫応答を改変するための材料および方法
GB0509845D0 (en) 2005-05-13 2005-06-22 Btg Int Ltd Preparation of therapeutic foam
CA2818182C (en) 2005-06-21 2015-04-14 Shire Regenerative Medicine, Inc. Methods and compositions for enhancing vascular access
US20090222086A1 (en) 2005-10-12 2009-09-03 Ge Ming Lui Resorbable Cornea Button
WO2007053799A2 (en) * 2005-10-19 2007-05-10 Cd Solutions, Llc Apparatus and method for mixing and transferring medications
PL1951344T3 (pl) * 2005-11-07 2015-02-27 Borla Ind Odpowietrzana bezpieczna podczas obsługi przystawka pośrednicząca do fiolki

Also Published As

Publication number Publication date
HK1116829A1 (en) 2009-01-02
JP2012224644A (ja) 2012-11-15
EP1874919B1 (de) 2010-06-09
US20090087414A1 (en) 2009-04-02
US20130177600A1 (en) 2013-07-11
JP5174656B2 (ja) 2013-04-03
CN101268183B (zh) 2011-11-30
US9040092B2 (en) 2015-05-26
CA2605080A1 (en) 2006-11-02
WO2006116357A1 (en) 2006-11-02
ATE470701T1 (de) 2010-06-15
AU2006238892B2 (en) 2011-01-27
AU2006238892A1 (en) 2006-11-02
CN101268183A (zh) 2008-09-17
JP2008538587A (ja) 2008-10-30
ES2347078T3 (es) 2010-10-25
EP1874919A1 (de) 2008-01-09
US20120308610A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
DE602006014814D1 (de) Materialien und verfahren zur änderung einer immunreaktion auf exogene und endogene immunogene, einschliesslich genidentischer und nicht-genidentischer zellen, gewebe oder organe
Birla et al. Myocardial engineering in vivo: formation and characterization of contractile, vascularized three-dimensional cardiac tissue
US10959833B2 (en) Implantable prosthesis having acellular tissue attachments
ES2706401T3 (es) Estructura saquiforme con actividad paracrina y métodos para su preparación
Machingal et al. A tissue-engineered muscle repair construct for functional restoration of an irrecoverable muscle injury in a murine model
ES2520019T3 (es) Mejoras relativas a la descelularización de matrices de tejido para el implante de vejiga
Kirsner The use of Apligraf in acute wounds
Iyyanki et al. Adipose-derived stem-cell-seeded non-cross-linked porcine acellular dermal matrix increases cellular infiltration, vascular infiltration, and mechanical strength of ventral hernia repairs
WO2017185853A1 (zh) 一种复合细胞外基质成分生物材料
WO2012009377A3 (en) Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
WO2012002986A3 (en) Decellularized and delipidized extracellular matrix and methods of use
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
Lin et al. Cavernous nerve repair with allogenic adipose matrix and autologous adipose-derived stem cells
ES2926295T3 (es) Injerto de tejido
WO2004009767A3 (en) Cell therapy for regeneration
ES2943332T3 (es) Producto sanitario de ingeniería tisular
ES2761307T3 (es) Proceso para la producción de parches o apósitos de piel autóloga mediante cultivo de queratinocitos y fibroblastos autólogos con suero autólogo para generación de piel
CN105682697B (zh) 去除α-半乳糖的方法
Katerinaki et al. Histological appearance of Stratticetm tissue matrix used in breast reconstruction
RU2017125478A (ru) Биосовместимые имплантаты, содержащие сконструированные эндотелиальные клетки
Mestak et al. Mesenchymal Stem Cells Seeded on Cross‐Linked and Noncross‐Linked Acellular Porcine Dermal Scaffolds for Long‐Term Full‐Thickness Hernia Repair in a Small Animal Model
Ladd et al. Bioreactor maintained living skin matrix
KR20010072553A (ko) 살아있는 키메릭 피부 대체물
CN107890586B (zh) 一种同种异体生物乳房补片的制备方法
JP5127120B2 (ja) 結合組織体形成基材およびそれを用いた結合組織体の製造方法